Achievement of Therapeutic Goals and Utilization of Evidence-Based Cardiovascular Therapies in Coronary Heart Disease Patients With Chronic Kidney Disease

American Journal of Cardiology

Volumn 101, Issue 8, 2008, Pages 1098-1102

  Lahoz, Carlos ^a   Mostaza, Jose M ^a   Mantilla, María Teresa ^b   Taboada, Manuel ^c   Tranche, Salvador ^d   López Rodriguez, Isidro ^e   Monteiro, Beatriz ^f   Soler, Begoña ^g   Sanchez Zamorano, Miguel A ^f   Martin Jadraque, Raquel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Centro de Salud Mar Baltico   (Spain)

^c Centro de Salud Fuencarral   (Spain)

^d Centro de Salud El Cristo   (Spain)

^e Centro de Salud de Begonte   (Spain)

^f Cardiovascular Department   (Spain)

^g CRO E C BIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; STATINE DERIVATIVE;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, LDL; CHRONIC DISEASE; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIURETICS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 41549095403     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.12.009     Document Type: Article

References (21)

1. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
2. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
3. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., Kitzmiller J., Knowler W.C., Lebovitz H., Lernmark A., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
4. Anavekar N.S., McMurray J.J., Velazquez E.J., Solomon S.D., Kober L., Rouleau J.L., White H.D., Nordlander R., Maggioni A., Dickstein K., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
5. Ezekowitz J., McAlister F.A., Humphries K.H., Norris C.M., Tonelli M., Ghali W.A., and Knudtson M.L. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44 (2004) 1587-1592
6. Parikh N.I., Hwang S.J., Larson M.G., Meigs J.B., Levy D., and Fox C.S. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 166 (2006) 1884-1891
7. Han J.H., Chandra A., Mulgund J., Roe M.T., Peterson E.D., Szczech L.A., Patel U., Ohman E.M., Lindsell C.J., and Gibler W.B. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 119 (2006) 248-254
8. Berger A.K., Duval S., and Krumholz H.M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42 (2003) 201-208
9. Newby L.K., LaPointe N.M., Chen A.Y., Kramer J.M., Hammill B.G., DeLong E.R., Muhlbaier L.H., and Califf R.M. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212
10. Mukherjee D., Fang J., Chetcuti S., Moscucci M., Kline-Rogers E., and Eagle K.A. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109 (2004) 745-749
11. Coca S.G., Krumholz H.M., Garg A.X., and Parikh C.R. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296 (2006) 1377-1384
12. McCullough P.A., Sandberg K.R., Borzak S., Hudson M.P., Garg M., and Manley H.J. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144 (2002) 226-232
13. Tonelli M., Moye L., Sacks F.M., Kiberd B., and Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 (2003) 98-104
14. Sarnak M.J., Greene T., Wang X., Beck G., Kusek J.W., Collins A.J., and Levey A.S. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 142 (2005) 342-351
15. Peterson J.C., Adler S., Burkart J.M., Greene T., Hebert L.A., Hunsicker L.G., King A.J., Klahr S., Massry S.G., and Seifter J.L. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123 (1995) 754-762
16. Marín R., Fernandez-Vega F., Gorostidi M., Ruilope L.M., Diez J., Praga M., Herrero P., Alcazar J.M., Laviades C., and Aranda P. Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. J Hypertens 24 (2006) 395-402
17. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59 (2001) 260-269
18. Banegas J.R., Vegazo O., Serrano P., Luengo E., Mantilla T., Fernandez R., and Civeira F. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis 188 (2006) 420-424
19. Diamantopoulos E.J., Athyros V.G., Yfanti G.K., Migdalis E.N., Elisaf M., Vardas P.E., Manolis A.S., Karamitsos D.T., Ganotakis E.S., and Hatseras D. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) study. Angiology 56 (2005) 731-741
20. Mosca L., Merz N.B., Blumenthal R.S., Cziraky M.J., Fabunmi R.P., Sarawate C., Watson K.E., Willey V.J., and Stanek E.J. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111 (2005) 488-493
21. Pearson T.A., Laurora I., Chu H., and Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467